Celebrations continue at Galderma Laboratories with the milestone of its new Research and Development center.
Forecast to be complete in the first quarter of 2017, the new center will expand the company’s North American headquarters, adding 100,000 square feet to the currently 170,000-square-foot campus. The new training, R&D, and office buildings will bring up to 350 new positions to the dermatology and skin health company’s headquarters, at an estimated price tag of $22 million.
“This expansion shows Galderma’s commitment to both skin health innovation and the Fort Worth community,” says Miles Harrison, general manager and president, Galderma North America, in a company news release. “It’s a game changer in that it will allow us to double the number of staff at our North American headquarters, increase our talent, and concentrate on our one and only focus, providing for skin health needs at every stage of life.”
Founded in 1961, Galderma currently employs more than 6,000 employees worldwide and has a presence as a dermatology and skin health global leader in 100 countries. The company’s portfolio includes prescription, aesthetic, self-medication, and corrective medical solutions to consumers, patients, and healthcare practitioners. One of the company’s well-known consumer lines is Cetaphil and aesthetic injectables under the Restalane Silk and Restylane Lyft brand names.
“We are proud that Galderma chose to invest in R&D and expand its Fort Worth footprint,” states Betsy Price, mayor of Fort Worth, in the release. “We appreciate the company’s commitment to creating hundreds of new jobs here in Fort Worth and look forward to mutual continued growth and success in our city.”
[Source(s): Galderma Laboratories, PR Newswire]